JAK2 and essential thrombocythemia: In adults diagnosed with ET JAK2-V617F mutations are detected in approximately 55%, CALR mutations in 15–24%, and MPL mutations in 4% of cases, whereas around 20% of patients display no mutations in the three hotspot genes, which is referred to as “triple-negative” or “triple-wildtype” [11, 12].